+ phenotype. Ter-cells are enriched in the enlarged spleen of hosts bearing advanced tumors and facilitate tumor progression by secreting neurotrophic factor artemin into the blood. Transforming growth factor b (TGF-b) and Smad3 activation are important in Ter-cell generation. In vivo blockade of Ter-cell-derived artemin inhibits hepatocellular carcinoma (HCC) growth, and artemin deficiency abolishes Ter-cells' tumor-promoting ability. We confirm the presence of splenic artemin-positive Ter-cells in human HCC patients and show that significantly elevated serum artemin correlates with poor prognosis. We propose that Ter-cells and the secreted artemin play important roles in cancer progression with prognostic and therapeutic implications.
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In Brief A population of immune cells in the erythroid lineage are induced in a mouse model of hepatocellular carcinoma, which promotes tumor progression through artemin production.
INTRODUCTION
Non-neoplastic cell populations in the tumor microenvironment have been reported to not only play critical roles in cancer progression but also be educated or reprogrammed by the microenvironment itself. Targeting the tumor microenvironment is increasingly considered as a promising approach for cancer intervention (Shalapour et al., 2015; Peng et al., 2015) . For example, some of these tumor-educated cell populations, such as tumor-associated macrophages (TAMs), myeloidderived suppressor cells (MDSCs), and regulatory T (Treg) cells are being explored as potential drug targets (Hanahan and Coussens, 2012; Elinav et al., 2013; Finn, 2012) . Interestingly, most of the tumor-promoting cell populations educated in the tumor microenvironment that have been identified to date are leukocyte subsets originated from myeloid cells.
Primary tumors can actively induce inflammatory, immunosuppressive changes and other tumor-promoting consequences in distant organs, facilitating tumor progression and metastasis. Identifying tumor-induced or expanded cell populations outside of the tumor microenvironment and their derived circulating factors thus become increasingly critical in understanding cancer as a systemic disease and exploring more effective prognosis and treatment strategies. For example, primary tumor-induced recruitment of neutrophils to distant organs can facilitate metastasis formation (Coffelt et al., 2015; Liu et al., 2016) . Furthermore, platelets can protect tumor cells from immune elimination in the circulatory system and support their establishment in secondary lesions (Gay and Felding-Habermann, 2011; Labelle et al., 2011) , further suggesting an important role of non-leukocyte cell populations outside of the tumor microenvironment in promoting tumor metastasis. Nevertheless, the full spectrum of non-leukocyte cell populations involved in different stages of tumor progression and their functional roles are still poorly defined.
The spleen of tumor-bearing hosts is usually enlarged, especially at later or more advanced stages (Miluzio et al., 2011) . Splenectomy has been proposed to be a clinical option for treating massive splenomegaly in advanced cancer patients with severe anemia (Taner et al., 2013) . As the spleen is an important immune organ outside of the tumor microenvironment, the roles of spleen in tumor-host interaction and tumor progression need to be carefully studied. Spleen is a reserve erythropoietic organ, thus an important question is whether new non-leukocyte cell populations are induced in the spleen by the tumor, and if so, what roles these cells play during tumor progression. Our goal for this study is to identify new non-leukocyte cellular subsets from the spleen that might be significantly expanded at the later stage of tumor challenge and have significant roles during tumor progression.
RESULTS

Discovery and Characterization of Ter-119 + CD45
À CD71 + Cells (Ter-Cells)
CD45 is a leukocyte common marker. To discover new tumorinduced non-leukocyte cell populations, we examined the known immune cells (all CD45 + ) and non-leukocyte cell populations (CD45 À ) in the main lymph organs of tumor-bearing mice, including spleen, lymph node, and bone marrow. We first established a murine orthotopic hepatocellular carcinoma (HCC) model by injecting murine Hepa HCC cells into the liver of C57/ BL6 mice and then examined cell populations in the main lymph organs. We found that the cell populations in the enlarged spleen significantly changed as HCC progressed. Monitoring of the splenocytes suggested that the proportion of almost all known immune cells, including T cells, B cells, natural killer (NK) cells, and macrophages, decreased along with tumor progression. Although MDSCs expanded during HCC progression, their proportion also decreased at the later stage (after 3 weeks, as the mice begin to die 5 weeks post inoculation).
To identify unknown CD45 À non-leukocyte cell populations induced or expanded by tumor in the spleen, we examined the expression of CD45 in splenocytes from Hepa HCC-bearing mice 4 weeks post inoculation. After lysis and removal of erythrocytes using Cl, all the splenocytes from normal mice expressed CD45, but unexpectedly, we found a population of non-leukocyte cells (CD45 À ) in splenocytes significantly expanded at the later stage of tumor challenge ($37.2% of splenocytes shown in 4 weeks post tumor inoculation). Cell sizes of this population were smaller than conventional leukocytes, and interestingly, these non-leukocyte cells (CD45 À ) were not detected in the spleen of normal mice ( Figure 1A ). We then analyzed the phenotype of these small CD45 À splenocytes and found that they did not express most lineage markers but did express Ter-119 ($99.4%, erythrocytes common marker), CD71 ($89.2%, marker of erythroid precursors), and CD41 ($31.7%, marker of platelets and megakaryocytes) (Figures 1B and S1A) . These data suggest that a new non-leukocyte cell population is induced in the spleen of HCC-bearing mice and that it shares the markers of erythroid cells and platelet-forming megakaryocytes.
To understand the origin or lineage characteristics of this cell population newly generated in advanced tumor-bearing mice, we further identify its surface marker expression phenotype to be Ter-119 + CD45 Figures 1B and S1A ). We named this cell population Ter-cells. Ter-119 is a marker for erythrocytes at differentiation stages from early proerythroblasts to mature erythrocytes. CD71 and CD44 are markers for erythroid precursors but not mature erythrocytes. Additionally, CD41 is a marker of megakaryocytic lineage and also marks the onset of murine primitive and definitive hematopoiesis (Robin et al., 2011) . The expression of CD41 also supports the idea that this cell population is derived from hematogenous origin. Expression of Ter-119 and CD44 was confirmed by confocal laser microscopy ( Figure 1C ). Electron microscopy revealed that Ter-cells had scant cytoplasm, a high nucleus/cytoplasm ratio, dense chromatin, and few cell organelles (Figure 1D Figures 1E and S1B ). For the expression of transcriptional factors and functional genes in hematopoiesis, we found that the cell population expressed transcriptional factors and functional genes associated with erythrocyte and megakaryocyte development, but not myeloid cells differentiation (Figure 1F) , suggesting that these cells may be derived from MEP during erythrocyte development. For example, Fli1 is an important megakaryoid lineage-determining transcription factor, Mpl and Pf4 are (G) The proportion of Ter-cells in the spleen, tumor mass, liver, draining lymph node (LN), bone marrow, and lung from normal mice (Day 0) or Hepa HCC-bearing mice at indicated time. All data are shown as mean ± SD (n = 4, in vitro; n = 10, in vivo) or typical photographs of one representative experiment. Similar results were obtained in three independent experiments. *p < 0.05; **p < 0.01. See also Figure S1 and Table S1 . (legend continued on next page)
functional genes in erythrocytes and megakaryocytes (Pronk et al., 2007; Paul et al., 2015) , and these genes are highly expressed in both MEP and the tumor-induced new cell population, but low in CMP ( Figure 1F ). Thus, we designated this population of cells as Ter-cells that were derived from MEP and induced in the spleen of advanced tumor-bearing host and proposed that Ter-cells are orthochromatic erythroblast-like cells.
Ter-Cells Preferentially Exist in the Spleen of AdvancedTumor-Bearing Host In Hepa-bearing mice, Ter-cells mainly exist in the spleen, there are relatively very few in the tumor mass, and they are almost absent in draining lymph nodes, bone marrow, liver, and lung (Figure 1G) . Moreover, the proportion of Ter-cells in the spleen rises along with HCC progression. In addition to the experimental Hepa HCC-bearing mouse model, we also established two HCC mouse models: a DEN-induced primary HCC mouse model with tumors forming 8 months after a single injection of DEN and mimicking human primary HCC development , and a human HCC-bearing nude mouse model (SMMC-LTNM) constructed by transplanting histologically intact fresh human HCC tissues to form subcutaneous transplantation tumors in nude mice and then continuously maintained with subcutaneous passages (Hou et al., 2011) . Ter-cells were also verified to be induced in the spleen of these two HCC models (Figures 1H and S1C-S1E). Furthermore, we showed that the significantly induced Ter-cells in the spleen were not restricted to HCC models, but were also in the EG7 T lymphoma-bearing and B16 melanoma-bearing C57/BL6 mouse models ( Figure 1I ). Taken together, our data suggested that Ter-cells may be generally induced in the spleen of tumor-bearing hosts. In order to further confirm that Ter-cells were induced in the spleen but not recruited to spleen, we inoculated Hepa cells into the mice with splenectomy before inoculation and found that the induction of Ter-cells was abolished in the organs, including tumor tissue, of the mice lacking spleen ( Figure 1J ). As Ter-cells may derive from defective erythrocyte development, we found that erythrocytes and hemoglobin were decreased during tumor progression, while splenectomy before tumor inoculation or during tumor progression both attenuated decrement of erythrocytes ( Figure S1F ). Therefore, tumor induces the emergence of erythroblast-like Ter-cells in the spleen.
Transforming Growth Factor b and Smad3 Activation Contribute to the Generation of Ter-Cells To investigate the generation and differentiation of Ter-cells, we performed protein phosphorylation microArray to elucidate activated intracellular signaling pathways in Ter-cells. Smad3 was the most significantly phosphorylated signaling molecule in Ter-cells (Table S1 ). The activated Smad3 and Smad2 were confirmed by western blot in Ter-cells ( Figure 1K ). In Smad3-deficient mice, Hepa inoculation-induced splenic Ter-cells were significantly reduced ( Figure 1L ). As Smad activation, especially Smad3 activation, is well-accepted to be downstream of transforming growth factor b (TGF-b), and TGF-b is known to potentiate differentiation of erythroblasts , we asked whether TGF-b, usually existing at high levels in the blood of the advanced cancer hosts (Matsuzaki et al., 2000; Song et al., 2002) ) and the control non-Ter-cells (CD45 + splenocytes) in Hepa HCC-bearing mice 4 weeks post inoculation were sorted and examined. Compared with control, Ter-cells had a set of genes significantly upregulated, and artemin expression was the most markedly increased (Figure 2A ). The microarray data also suggest that Ter-cells do not express most immune-related mediators, such as IL-4, IL-6, IL-10, TGF-b, IP-10, MIP-1a, MIP-1b, MIP-2, or PGE-2 (data not shown). Increased artemin expression by Ter-cells was also confirmed by qRT-PCR, ELISA, and western blot ( Figures 2B-2D) . Therefore, the neurotrophic factor artemin is preferentially overexpressed in Ter-cells.
We found Ter-119 and artemin double-positive cells in the spleen of Hepa HCC-bearing mice and DEN-induced primary HCC mice ( Figure 2E ). In the main organs, including lung, kidney, lymph nodes, and bone marrow, we did not find elevated artemin expression or Ter-119/artemin double-positive cells (data not shown). These findings confirm that Ter-cells in the spleen of HCC-bearing mice can secrete artemin. To determine whether (F and G) IHC (F) and immunofluorescence (G) of CD235A or artemin staining were performed in the spleen tissues from HCC patients and healthy donors. Typical photographs were from HCC patients with TNM stage III. Scale bars, 50 mm (F), 10 mm (G) . Ter-cells occur in human HCC, we also examined the spleen tissue samples of HCC patients and confirmed that CD235A (human ortholog of Ter-119) and artemin double-positive cells were present in the spleen of HCC patients (Figures 2F and 2G) . These data, therefore, demonstrate that artemin is expressed by Ter-cells in the spleen of HCC patients.
The above data indicate that production of artemin by splenic Ter-cells may contribute to a higher level of artemin in the sera of tumor-bearing hosts. For the role of neuropeptides in cancer, cancer cells can invade and deregulate the neuroendocrine system, and neuropeptides can be expressed by cancer cells and contribute to cancer progression (Airaksinen and Saarma, 2002; Hansford and Marshall, 2005) . Neurotrophic factor artemin belongs to the glial cell line-derived neurotrophic factor (GDNF) family, which includes GDNF, neurturin, persephin, and artemin (Hondermarck, 2012; Ito et al., 2005) . As the role of serum artemin in tumor progression is currently unknown, we went further to study the level of circulating artemin in tumor-bearing hosts and its role in tumor progression.
Serum Artemin Is Derived from Splenic Ter-Cells and Increased in Tumor Models
Given that Ter-cells mainly exist in the spleen of HCC-bearing mice and secrete artemin, we investigated serum level of artemin in our mouse models of HCC and whether the serum artemin was derived from Ter-cells in the spleen. We found significantly increased serum artemin during HCC progression in all 3 of our HCC mouse models as well as a xenograft model (Figures 2H-2J and S2E). Serum artemin was significantly reduced in Hepabearing Smad3-deficient mice (Figure 2K) , consistent with TGF-b being important for Ter-cell generation. Additionally, in a HepG2 xenograft model, the elevated serum artemin was mainly mouse artemin but not human artemin (Figure S2F) , suggesting that elevated serum artemin was primarily from Ter-cells instead of from the cancer cells.
To further confirm artemin is primarily from Ter-cells, we performed splenectomy before tumor inoculation or during tumor progression in Hepa-bearing mouse. Elevated serum artemin was nearly abolished in mice with splenectomy before tumor inoculation while significantly decreased by splenectomy during tumor progression (Figure 2L) , confirming that splenic Ter-cells are the main source of serum artemin in the tumor-bearing mice. We also inoculated the mice with artemin-knockout Hepa cells and found that splenic Ter-cell induction, serum artemin, and HCC growth were not significantly influenced as compared to controls ( Figures S2G-S2J ), further confirming that serum artemin is mainly from Ter-cells but not cancer cells.
Serum Artemin Is Increased in HCC Patients and Correlated with Poor Prognosis
Next, we examined the roles of the increased serum artemin in HCC progression. To translate the basic observations above to the clinic, we explored serum levels of artemin in healthy donors, in patients with chronic hepatitis B and liver cirrhosis, and in HCC patients from four independent cohorts (Table S2) . Serum artemin was found to be significantly higher in HCC patients, and much less serum artemin was present in all the controls (Figure 3A) . Furthermore, after curative resection of HCC mass, serum artemin in patients of cohorts 3 and 4 was significantly decreased (Figure 3B , serum samples after surgery are available only in these two cohorts). This result further validates the importance of serum artemin level in HCC patients.
Because TGF-b is important for Ter-cell generation and artemin production, we examined the correlation between serum TGF-b and artemin. As shown in Figures 3C and 3D , serum TGF-b was positively correlated with serum artemin in HCC patients, and serum TGF-b was also decreased by curative resection of HCC. Thus, surgical resection of HCC tissues may decrease serum TGF-b level and then inhibit Ter-cell generation and consequently lead to less artemin production.
As serum artemin is increased in HCC patients, we analyzed the correlation between serum artemin and prognosis of HCC patients. As shown in Figure 3E , HCC patients in cohorts 1 and 2 with higher serum artemin had a poorer prognosis than those with lower serum artemin. Cox proportional hazards regression analysis also determined that higher serum artemin is an independent predictor for reduced disease-free survival of HCC patients (Table S3) . Together, serum artemin is increased in HCC patients and correlated with poor prognosis, suggesting that serum artemin may be a new prognosis factor for HCC patients.
Increased Artemin Receptor Expression Correlates with HCC Patients' Poor Prognosis
Artemin activates downstream signals mainly through its receptor GFRa3 and phosphorylation of the co-receptor RET. We found GFRa3 expression and RET phosphorylation were both elevated in human HCC tissues (Figure 4A) . Correlation assay in the analyzed HCC cohorts showed that serum artemin was positively correlated with GFRa3 expression and RET phosphorylation in HCC tissues ( Figures 4B and 4C) , further suggesting the presence of activated artemin signaling in HCC. Moreover, as with serum artemin, patients with relatively higher GFRa3 expression levels or higher RET phosphorylation levels in HCC tissues had shorter disease-free survival than those with relative lower levels ( Figures 4D and 4E ), as determined in cohorts 1 and 2 using the median level as the cutoff, respectively. The higher expression of GFRa3 or phosphorylation of RET in HCC tissues are also independent predictors for poor prognosis in HCC patients (Tables S4 and S5 ). Hence, an activated artemin signaling pathway in HCC tissue may also predict poor prognosis.
Ter-Cell-Derived Artemin Promotes Tumor Progression Both In Vitro and In Vivo
The increased artemin in the blood and the activated artemin signaling in HCC tissue prompted us to investigate the roles of (E) Increased serum level of artemin is correlated with reduced disease-free survival of HCC patients. Shown are Kaplan-Meier survival curves of disease-free survival in cohorts 1 and 2. The median level of serum artemin in each cohort was chosen as the cutoff point as median value is commonly used as the cutoff, with log-rank test for significance. See also Tables S2 and S3. artemin in HCC progression. Recombinant human artemin significantly promoted cell viability, colony formation, migration, and invasion of HCC cell lines in vitro (Figures 5A-5C and S3A-S3C). Ter-cells also promoted HCC Hepa and lymphoma EG7 cell migration and invasion, and these effects could be significantly inhibited by the neutralizing antibody against artemin ( Figures 5D, 5E , and S3D). The human and mouse artemin were suggested to be highly homogeneous, and mouse artemin could activate the downstream signaling in human HCC cells (Figures S3E and S3F) . Artemin produced by Ter-cells promotes cancer cell survival, invasion, and migration in vitro.
Caudal vein injection of recombinant human artemin significantly promoted tumor growth and HCC-related death in HepG2 xenografts and in the human HCC-bearing nude mouse model SMMC-LTNM ( Figures 5F and 5G) . In vivo administration of Ter-cells promoted HCC Hepa and lymphoma EG7 growth and tumor-related death, and this effect could be suppressed by caudal vein injection of neutralizing antibody against mouse artemin ( Figures 5H and S3G) . Thus, Ter-cell-derived artemin can promote tumor progression both in vitro and in vivo.
Artemin Promotes HCC Progression by Inducing Caspase-9 Thr125 Phosphorylation and Upregulating TRIOBP and ITGB5 Expression Mechanistically, we studied the effector signaling of artemin in HCC cells and found recombinant artemin significantly (A) The protein levels of GFRa3 and phosphorylated RET in human normal liver tissues, para-HCC tissues, and HCC tissues were detected by IHC and measured by defining regions of interest (ROI) using automated cell acquisition and quantification software for IHC. (B) The correlation between serum level of artemin in HCC patients and the expression of its receptor GFRa3 in HCC tissues derived from cohorts 1 and 2 was analyzed by Pearson's correlation coefficient assay with R and p values indicated. (C) The correlation between serum level of artemin in HCC patients and RET phosphorylation in HCC tissues derived from cohorts 1 and 2 was analyzed by Pearson's correlation coefficient assay with R and p values indicated. (D) The higher GFRa3 mRNA expression in HCC tissues is correlated with the reduced disease-free survival of HCC patients. Shown are Kaplan-Meier survival curves of disease-free survival in cohorts 1 and 2. The median value of GFRa3 mRNA expression in each cohort was chosen as the cutoff point, with log-rank test for significance. (E) The higher RET phosphorylation in HCC tissues is correlated with the reduced disease-free survival of HCC patients. Shown are Kaplan-Meier survival curves of disease-free survival in cohorts 1 and 2. The median value of RET phosphorylation in each cohort was chosen as the cutoff point, with log-rank test for significance. See also Tables S4 and S5. A) HCC SMMC-7721 and HepG2 cells were stimulated with recombinant human artemin at indicated concentrations in rapamycin (10 ng/mL) for 24 hr, then cells were stained using propidium iodide (PI) and annexin V and analyzed by fluorescence-activated cell sorting (FACS). The annexin V-positive cells were regarded as apoptotic cells. (B and C) SMMC-7721 or HepG2 cells were pretreated with recombinant human artemin at indicated concentrations for 2 hr, then added to the upper compartment of the chamber and incubated for 12 hr (for migration assay) or 24 hr (for invasion assay). Cells adhered to the lower surface were fixed and stained, and the cell number was counted. (D and E) Hepa cells were treated with Ter-cells, Ter-cells plus neutralizing antibody against mouse artemin, or recombinant mouse artemin as indicated. Cells were treated with rapamycin, and apoptosis was determined using annexin V/PI staining (D) . Cells invaded to the lower surface were fixed, stained, and counted as indicated (E) . (F and G) After subcutaneous inoculation of HepG2 cells (F) or transplantation of SMMC-LTNM tumor tissues (G) into nude mice, recombinant human artemin was delivered by tail vein injection once every 2 days for 14 days, then tumor growth (upper graphs) and survival (lower graphs) of HCC-bearing nude mice were detected as indicated.
(legend continued on next page) increased its receptor GFRa3 expression and RET phosphorylation in SMMC-7721 and HepG2 HCC cells in vitro ( Figures 6A-6D and S4A-S4F). In vivo administrations of recombinant human artemin also promoted GFRa3 expression and RET phosphorylation in tumor tissues of human HCC-bearing mouse model SMMC-LTNM ( Figure 6E ). We also confirmed that artemin did activate pro-survival MAPK and PI-3K pathways in HCC cells, as shown by the enhanced phosphorylation of ERK, p38, and Akt ( Figures 6F, S4G, and S4H) .
To investigate artemin-induced downstream pathways and gene expression responsible for artemin-promoted HCC survival and invasion, we performed protein phosphorylation microarray and gene expression cDNA microarray in SMMC-7721 HCC cells upon artemin stimulation. Artemin induced the phosphorylation of a set of intracellular proteins (Table S6 ) and the most induced was the phosphorylation of caspase-9 at position threonine 125 (Thr125). The phosphorylation of caspase-9 at Thr125 is crucial to inhibit caspase-9 activation and apoptosis initiation, which is directly mediated by ERK activation (Allan et al., 2003; Martin et al., 2008) . Accordingly, ERK inhibitor PD98059 markedly inhibited the artemin-induced phosphorylation of caspase-9 Thr125 ( Figure 6G) . Furthermore, the inactivated mutant caspase-9 T125A significantly blocked the artemin-promoted survival of SMMC-7721 cells ( Figure 6H ). Thus, artemin promotes HCC survival, at least partially, by activating downstream ERK to phosphorylate caspase-9 at inhibitory site Thr125, which in turn inhibits caspase activation and apoptosis initiation.
In addition, a set of artemin-stimulated genes was identified and confirmed by qRT-PCR ( Figures 6I and S4I) . By screening the effects of knocking down these genes on HCC invasion, we found that knockdown of TRIOBP or ITGB5 could inhibit artemin-promoted cell invasion, respectively. Moreover, knockdown of both TRIOBP and ITGB5 nearly abolished artemin-promoted HCC invasion ( Figures 6J, S4J , and S4K). Artemin-induced TRIOBP was PI-3K-dependent, and artemin-induced ITGB5 was PI-3K-and p38-dependent ( Figure 6K ). Thus, TRIOBP and ITGB5 were responsible for artemin-promoted HCC invasion. Taken together, artemin activates ERK pathway to phosphorylate caspase-9 at the inhibitory site Thr125 and then inhibits the apoptosis. Moreover, artemin induces the expression of TRIOBP and ITGB5 to at least partially enhance HCC invasion.
Caspase-9 Thr125 phosphorylation and TRIOBP, ITGB5 expression in HCC tissues were all positively correlated with the serum level of artemin in both cohort 1 and 2 HCC patients (Figure S4L) . Furthermore, higher caspase-9 Thr125 phosphorylation, higher expression of TRIOBP, or ITGB5 in HCC tissues were all correlated with poor prognosis in HCC patients ( Figure S4M ). Together with the in vitro data that artemin promotes HCC survival and invasion by phosphorylating caspase-9 at Thr125 and induces TRIOBP and ITGB5 expression, these results further elucidate the importance of serum artemin and artemin-induced activation of intracellular signaling in HCC progression.
Blockade of Ter-Cell-Derived Artemin or Its Receptor GFRa3 Signaling Inhibits HCC Growth In Vivo Finally, we evaluated whether the intervention of serum artemin or downstream artemin signaling could represent therapeutic approaches for HCC. We found that in vivo administration of a neutralizing antibody against mouse artemin significantly suppressed tumor growth and HCC-related animal death in HepG2 xenograft and SMMC-LTNM models and in the DENinduced mouse model (Figures 7A-7C) . Accordingly, GFRa3 expression and RET phosphorylation were suppressed in the SMMC-LTNM model ( Figure S5A ). These results suggest that blockade of artemin could be a new approach for HCC therapy.
Moreover, the artemin knockout mice were generated, and these mice were fertile and seemed normal. HCC tumor growth was significantly reduced in artemin knockout mice as compared to wild-type littermates both in the DEN-induced primary HCC model and Hepa HCC-bearing model ( Figures 7C and  7D) . Moreover, the tumor growth of artemin-deficient Hepa cells was similar to that of control Hepa cells when both cell types were inoculated into artemin-knockout mice, respectively (Figure 7D) , further arguing that Ter-cell-derived artemin, but not cancer cell-derived artemin, promotes cancer progression. Additionally, splenectomy inhibited tumor growth and prolonged survival of orthotropic HCC Hepa-bearing mice ( Figure 7E ). Adoptively transferring artemin +/+ Ter-cells also promoted HCC tumor growth more significantly than adoptively transferring artemin À/À Ter-cells in splenectomized mice, indicating that artemin deficiency almost abolished the ability of Ter-cells to promote HCC growth ( Figure 7F ). Furthermore, we evaluated the effects of artemin signaling blockade on HCC progression. In GFRa3 stably silenced HepG2 cells with reduced GFRa3 expression ( Figures S5B and  S5C) , the promotion of cell survival, migration, and invasion by artemin was significantly attenuated (Figures S5D-S5F ). In the HepG2 xenograft model, RET phosphorylation was reduced, and tumor growth and HCC-related death were also significantly suppressed in vivo by GFRa3 knockdown (Figures 7G and S5G) . Together, these results suggest that promotion of tumor growth by Ter-cells is mediated by their artemin secretion. Blockade of artemin and/or its downstream signaling or splenectomy could be therapeutically useful for human HCC.
DISCUSSION
In this study, we identified a tumor-induced new population of erythroblast-like Ter-119 + Ter-cells in the spleen of tumorbearing mice. Ter-119 antibody can specifically react with erythrocytes at differentiation stages from early proerythroblasts to mature erythrocytes (Chen et al., 2009) and is the marker of erythrocyte from early proerythroblasts to mature erythrocytes (Kina et al., 2000) . Transcriptome analysis of Ter-cells (H) Hepa-bearing mice were treated with Ter-cells, Ter-cells plus neutralizing antibody against mouse artemin, and recombinant mouse artemin, with normal goat IgG control as indicated. Tumor growth (upper graph) and survival of mice (lower graph) are indicated. Data are shown as mean ± SD (n = 10) or indicated directly. Similar results were obtained in three independent experiments. *p < 0.05; **p < 0.01. See also Figure S3 .
determines that Ter-cells express erythropoiesis-associated transcriptional factors and functional genes and they may be derived from MEP during erythrocyte and megakaryocyte development. In the future, single-cell sequencing of Ter-cells from different cancer models at different stages, with or without deficiency of TGF-b or other molecules, will contribute to a better understanding of the lineage differentiation of this cell population in the context of tumor-host interaction.
Regarding tumor-induced leukocyte populations, MDSC is a heterogeneous population of cells that consists of myeloid Figure S4 and Table S6. progenitor cells and immature myeloid cells, which can be induced by tumors and expanded in the bone marrow and then recruited to peripheral regions including the spleen (Gabrilovich and Nagaraj, 2009). MDSCs possess significant capabilities of suppressing anti-tumor T cell responses and promoting tumor angiogenesis and metastasis (Gabrilovich and Nagaraj, 2009 ). However, unlike MDSCs, which exist in bone marrow, peripheral blood, spleen, lymph node, and tumor mass (Gabrilovich and Nagaraj, 2009 ), Ter-cells preferentially exist in the spleen of the tumor-bearing hosts and promote cancer progression through artemin production but without influence on antitumor immunity. The splenic microenvironment may also be important for the generation of Ter-cells and their artemin production, an area that still needs further investigation in the future. We find that Ter-cells are induced exclusively in the spleen. The spleen is a reserve erythropoietic organ, whereas bone marrow is an active site of erythropoiesis in the physiological state. Stress, such as anemia or tissue hypoxia, could induce the reappearance of splenic erythropoiesis (Guihard et al., 2010; Spivak, 2005; Dicato et al., 2010) . Tumors may interfere with splenic erythropoiesis, resulting in the accumulation of late erythroid precursors and the differentiation into Ter-cells under TGF-b. This may be a new mechanism that can explain anemia or low platelet syndrome in cancer patients, especially with late-stage dyscrasia. It is worth noting that the role of spleen as either a reservoir or an essential organ for the generation of Tercells is still not entirely proven, and the direct mechanism responsible for how spleen induces the generation of Ter-cells and whether they participate in anemia or low platelet syndrome still require further investigation. Moreover, as Ter-119 is an erythrocytic lineage-specific marker and is expressed on mature erythrocytes, erasing Ter-119-positive cells using Ter-119 may also kill the red blood cells. Identifying exclusive cell surface markers on Ter-cells and possible Ter-cell-specific transcriptional factor as surrogates may help with highly selective removal of these cells in the future.
Because Ter-cells are found mainly in the spleen of HCCbearing mice, we reasoned that resection of the spleen during HCC curative surgery may have favorable effects for HCC patients, as splenectomy has been shown to have clinical benefit in some gastric or colorectal cancer patients (McGory et al., 2007; Kunisaki et al., 2007) . Here, we found that splenectomy in mice suppressed HCC growth in vivo, although the effect was somewhat modest. It should be noted that there are many types of cells locating in the enlarged spleen of tumor-bearing host and they might have different effects on tumor progression via different mechanisms. The net effect of splenectomy on HCC progression will therefore be determined by many factors, known and still unknown. Specific removal of Ter-cells in the spleen may be more useful in the treatment of HCC patients. In addition, identifying other pro-tumor effector molecules from Ter-cells and their targeting strategies may be beneficial. Splenectomy is currently not yet approved clinically as a HCC curative surgical procedure. Our findings of the abolishment of Ter-cells and decrease of serum artemin and HCC growth of tumor-bearing mice after splenectomy further support the therapeutic potential of splenectomy in the treatment of advanced cancer patients.
We observed that serum artemin significantly decreased in HCC patients after curative resection of HCC mass, indicating that tumor mass may induce generation of the human counterpart to Ter-cells in the spleen of HCC patients; furthermore, this human counterpart decreased, as did the secretion of artemin, after curative surgery. In addition, the decrease of serum artemin in HCC patients after curative surgery may also be influenced by artemin production in HCC tissues, given that serum artemin can induce artemin expression in HCC cells, and artemin expression is thought to be increased in tumor tissues (Banerjee et al., 2012; Kang et al., 2009; He et al., 2014; Huber et al., 2015) . As this paper was being revised after peer review, also reported that artemin expression in HCC tissue and cells promotes oncogenicity of HCC cells and expansion of cancer stem cells in HCC. However, we speculate that the increased expression of artemin in tumor tissues may be a secondary event induced by the high serum artemin produced by splenic Tercells, as we found that inoculation with artemin-knockout Hepa cells can induce the generation of Ter-cells and increase of serum artemin similarly with wild-type Hepa cells. We also propose that splenic Ter-cells are the primary source of serum artemin, as no significant increase of serum artemin was observed in tumor-bearing mice that lack spleens. Additionally, although Smad3 activation was important for the generation of Ter-cells, why Ter-cells highly produce artemin remains elusive. We have tried to stimulate human erythroleukemia cell line HEL using TGF-b but did not observe artemin induction (data not shown).
Given that serum artemin is elevated in HCC patients, we have also tried to compare it with alpha-fetoprotein (AFP) in HCC diagnosis and found that it was less effective (data not shown). However, as AFP is less significant in survival analysis of HCC , serum artemin could be more significant in prognosis prediction and may sever as a therapeutic target, possibly because of the tumor-promoting effect of artemin. Now that a set of intracellular molecules has been reported to assist in HCC prognosis (Budhu et al., 2006; Hoshida et al., 2008) , the identification of serum artemin as a new prognosis predictor may be more applicable for HCC patients given that serum cytokines can be detected more easily and accurately than can intracellular molecules in HCC. Furthermore, other GDNF members or neurotrophic factors in serum may also be important in tumor progression. Future research may further reveal the role and significance of neurotrophic factors and their receptors in the systemic spread of cancer.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xuetao Cao (caoxt@immunol.org) with chronic hepatitis B and 88 patients with liver cirrhosis were from Beijing Youan Hospital (Beijing, China). The normal human spleen tissue samples are from patients with traumatic spleen injury during operation, and the informed consent was obtained according to international standards. The gender and age of HCC patients we used are listed in Table S2 , and they are statistically analyzed to be not significantly correlated with prognosis (Table S3) . Surgically removed tissues were quickly frozen in liquid nitrogen until analysis. All samples were collected with the informed consent of the patients, and the experiments were approved by an Institutional Research Ethics Committee at each research center.
Mice and cell lines C57BL/6 mice and nude mice were obtained from Joint Ventures Sipper BK Experimental Animal (Shanghai, China) and used at the ages of 6-8 weeks. The OVA-specific TCR transgenic OT-I and OT-II mice were obtained from the Jackson Laboratory, Smad3-deficient mice were kindly provided by Dr. Xiao Yang, the artemin knockout mouse was constructed by us through the deletion of Exon 4 in artemin gene locus using CRISPR/Cas9 techniques (Ma et al., 2016) , and these mice were bred in specific pathogen-free conditions. All experimental manipulations were undertaken in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of the Second Military Medical University, Shanghai, China. The murine HCC cell line Hepa, human HCC cell lines SMMC-7721, HepG2, QGY-7701, QGY-7703, BEL-7402, and BEL-7404 were maintained as described previously (Hou et al., 2011) .
METHOD DETAILS Reagents
The antibodies . Antibodies specific to ERK, p38, JNK, AKT, and their phosphorylation, and Smad3 (pSer425), Smad2 (pSer250), b-action, GAPDH, and horseradish peroxidase-coupled secondary antibodies were from Cell Signaling Technology (Danvers, MA) and have been described previously .
In vivo assay
The orthotopic hepatic tumor model was established by subcapsular intrahepatic injection of Hepa cells (1 3 10 6 /50 mL per mouse)
into the left liver lobe of mice. For preparation of the subcutaneous HCC-bearing nude mice model, 0.2 mL grinded SMMC-LTNM tumor tissue or 1 3 10 7 HepG2 cells were subcutaneously injected and inoculated. For chemical induction of hepatocarcinogenesis, mice at postnatal day 15 were injected intraperitoneally with 25 mg/kg DEN and then maintained on regular chow food. Liver, tumor, and spleen were harvested for analysis eight months after the initial injection. For evaluating the tumor-promoting effect of artemin or the anti-tumor effect of neutralizing antibody against artemin in vivo, recombinant mouse or human artemin (2 mg/mouse) or neutralizing antibody against mouse artemin (10 mg/mouse) were injected by caudal vein injection once every two days for 14 days, or injected twice a week form 6-8 months post DEN administration. Tumor size and survival of tumor-bearing mice were measured as described previously (Hou et al., 2011) .
Isolation of mononuclear cells from tumor mass, lung and liver Tumor mass, lung, and liver obtained from tumor-bearing mice at different times were digested with collagenase IV (Sigma-Aldrich) for 3 h, and then the single-cell suspension was passed through a 40-mm cell strainer (BD Falcon). Mononuclear cell (MNC) populations were separated by centrifugation through a Percoll gradient. Cells were collected, washed in PBS, and resuspended in 40% Percoll (Sigma-Aldrich) in complete RPMI 1640 medium. The cell suspension was then gently overlaid onto 70% Percoll and centrifuged. MNC were collected from the interface, washed twice in PBS, and resuspended in complete RPMI 1640 medium.
Reverse-transcription and Real-time PCR Total cellular RNA was extracted using Trizol reagent (Invitrogen). 2 mg total RNA was used in a 20 mL reverse-transcription reaction using the First Strand cDNA Synthesis kit (Toyobo). Real-time qRT-PCR assay was performed as described previously .
Apoptosis assay
HepG2 or SMMC-7721 cells were stimulated with recombinant human artemin at the indicated concentrations and Rapamycin (10 ng/ml) for 24 h, then cells were stained using Propidium iodide (PI) and Annexin V and analyzed by FACS (FACScalibur, Becton Dickinson, Mountain View, CA) as described previously . The Annexin V-positive cells were regarded as apoptotic cells.
In Vitro migration and invasion Assay Tumor cell migration was assayed in a 24-well Transwell cell culture chamber with filters of 8.0 mm pore size according to the manufacturer's instructions (Costar, Cambridge, MA). The invasiveness of tumor cells and transfectants was evaluated by the Matrigel (10 mm thickness and 8 mm pore size) assay using 24-well Boyden chambers (BD Biosciences, Bedford, MA) containing a polycarbonate membrane according to the manual. 5 3 10 4 cells in 500 mL RPMI 1640 medium were added to the upper compartment of chamber and incubated at 37 C for 12 h (for migration assay) or 24 h (for invasion assay). After incubation, the non-invading cells were removed from the upper surface of the membrane by wiping with a cotton-tipped swab. Cells adhered to the lower surface were fixed in 4% paraformaldehyde and then stained with 0.4% crystal violet. To calculate the total number of invading cells, the membranes were scanned and cell number in every microscopic cutout of the mosaic image of the membrane was counted using the software LAS V4.5 (Leica DM 2000).
Western blot
Cells were lysed and protein concentration was determined by BCA Protein Assay Kit (Pierce). Cell lysates were separated by SDS-PAGE gels and transferred to nitrocellulose membranes. The membranes were then blotted with the indicated antibodies. Proteins were visualized using SuperSignal West Femto Maximum Sensitivity Substrate, as instructed by the manufacturer (Pierce, Rockford, IL) and described previously Zheng et al., 2017) .
Immunohistochemistry
Paraffin-embedded tissue sections of normal liver, HCC and matched controls were analyzed by immunostaining using the DAKO Envision system. GFRa3, phosphorylated RET, and caspase-9 pThr125 antibodies were used at the dilution of 1:100. Rabbit polyclonal IgG (DAKO) was used as negative control instead of primary antibody. Digital imaging was performed using the software LAS V4.5 (Leica DM 2000). Pictures were also acquired using HistoFAXS system and mean DAB staining intensity was calculated using Histoquest software (both from TissueGnostics, Vienna, Austria) as we described previously .
Immunofluorescence
Tissue sections of spleen, lung, liver, lymph nodes or fixed HCC cell lines were analyzed by immunofluorescence. GFRa3 and phosphorylated RET antibodies were used at the dilution of 1:100. Ter-119, artemin and CD235A antibodies were used at the concentration of 25 mg/ml, 15 mg/ml, and 10 mg/ml respectively. The fluorescent-labeled second antibodies were used at the dilution of 1:100. Digital imaging was performed using the software LAS V4.5 (Leica DM 2000). Transfection 2 3 10 5 HepG2 cells were seeded into each well of 6-well plates and incubated overnight, then transfected with GFRa3 shRNA plasmids (design by GenePharma, China) using jetPEI (Polyplus-transfection, France) as described previously . Stably silenced transfected cell clones were selected in 800 mg/ml G418 for 3-4 weeks and then confirmed by real-time PCR and western blot for GFRa3 expression.
Flow cytometry and FACS
Before staining with fluorescent antibodies, all cells were incubated for 15 min at 4 C with antibodies to CD16/CD32 at a concentration of 1 mg/1 3 10 6 cells/100 mL for blockade of Fc receptors. Fluorescent antibodies and the respective isotype controls were then added at a concentration of 1 mg/1 3 10 6 cells/100 mL and cells were incubated for a further 30 min at 4 C. The cells were washed once with ice-cold PBS containing 0.1% NaN 3 and 0.5% BSA and resuspended in 200 mL PBS. Flow cytometry analysis was performed with a FACS LSRII (BD Biosciences) and data were analyzed with FACSDiva software. . The purity was confirmed by flow cytometry to be > 98%.
RNA-seq
Total RNAs were extracted and subjected to high throughput sequencing as previously reported (Zhang et al., 2015) . Genes with FPKM values above 10.0 in the cell groups were used for subsequent analysis. Single linkage clustering analysis between the groups and prcomp function-based PCA analysis on the expression matrix were performed by R software.
Assay for OVA-specific T cell proliferation in vitro Splenic CD4 T cells and CD8 T cells from OT-I and OT-II mice respectively were positively selected by magnetic-activated cell sorting for use as OVA-specific responders, and then were co-cultured for 5 d with live mDCs, together with or without Ter-cells, in the presence of OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] or OVA 257-264 at a ratio of 10:1 (T cells/DCs) (1 3 10 5 T cells in 200 ul/well). The ratios of T cells and Ter-cells were 1:1. Then, cells were stained with 7-AAD and anti-CD4 FITC or anti-CD8 FITC, re-suspended in 200 mL PBS, and cellular data were acquired for 70 s with a flow cytometer (1 3 10 5 PE-labeled beads 3 mm in diameter were added into each well as an internal control before antibodies labeling). The numbers of CD4 + 7-AAD -or CD8 + 7-AAD -live cells and control bead events acquired were analyzed, and the total cells in each well were calculated according to the formula: total no. = (no. live T cells/no. beads) 3 10 5 .
Electron microscopy Purified Ter-119 + CD45 -splenocytes from tumor-bearing mice were fixed in 2.5% glutaraldehyde in 0.1M sodium cacodylate buffer for 1h. After washing, cells were post-fixed in 1% osmium tetroxide for 2h, stained en bloc with uranyl acetate, dehydrated in a series of graded ethanol solutions, and embedded in an Epon/Araldite mixture. Ultrathin sections were stained with lead citrate and examined under an electron microscope (Nippon Denshi EX-200).
RNA Interference
SiRNAs and their matched negative controls were synthesized by GenePharma (Shanghai China). RNAs were transfected using INTERFERin TM (Polyplus-transfection) according to the manufacturer's instructions at a final concentration of 10 nM. For the stable knockdown of GFRa3 expression, shGFRa3 expressing plasmid with the transcript sequence 5 0 -GGA CAT CTA TTG GAC CGT TCA TTC AAG AGA TGA ACG GTC CAA TAG ATG TCC TT-3 0 was also purchased from GenePharma and transfected.
Construction of HCC cell lines using CRISPR/Cas9 techniques
Artemin knockout Hepa cells were constructed by the deletion of Exon 4 in artemin gene locus using CRISPR/Cas9 techniques. GFRa3 knockout HepG2 cells were constructed by the deletion of Exon 2 in GFRa3 gene locus, and TGF-b knockout Hepa cells were constructed by the deletion of Exon 2 in TGF-b1 gene locus using CRISPR/Cas9 technique. The artemin knockout mice and selected cell clones were confirmed by sequencing and the target gene expression were validated by western blot. The cell clones transfected with pGL3-U6-sgRNA-PGK-puromycin vector (#51133, Addgene) were used as controls (Ma et al., 2016) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± s.d. Statistical comparisons between experimental groups were analyzed by Student's t test, and a two-tailed p < 0.05 was taken to indicate statistical significance. Correlation was analyzed using Pearson's correlation coefficient assay in SPSS 17.0 with r and p values shown. For analyzing survival of HCC patients, log-rank test in SPSS 17.0 was used with the p values shown. Analysis of univariate or multivariate Cox proportional hazards regression was also conducted using SPSS 17.0 with the hazard ratios and p values shown.
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the cDNA microarray and RNA-seq data reported in this paper are GEO: GSE58468, GSE72411, and GSE109429. 
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